STAAR Surgical(US:STAA)2025-02-13 06:51Financial Performance & Outlook - FY24 GAAP Net Sales were $313.9 million[16], a 13% increase excluding China ICL sales[16] - China ICL sales decreased by 13% in FY24[23], and significantly dropped by 82% in Q4'24[23], reaching $7.5 million[16] - ICL Sales Ex China grew by 13% in FY24, reaching $151.6 million[16] - The company anticipates FY25 ICL Sales Ex China to be in the range of $165 million to $175 million, representing a 9% to 15% year-over-year increase[33] - The company projects China ICL Sales for FY25 to be between $75 million and $125 million[33] - The company anticipates an Adjusted EBITDA loss of approximately $50 million to $15 million for FY25[48] Regional Performance - Americas ICL sales increased by 15% in FY24[16], with Q4'24 showing a 22% increase[27] - EMEA ICL sales grew by 10% in FY24[16], and APAC Ex China ICL sales increased by 14%[16] - US ICL sales increased by 19% in FY24[29] Challenges & Strategies - Weak consumer confidence and macroeconomic headwinds in China significantly impacted ICL sales[14, 19] - The company estimates an approximate 15% decline in overall refractive procedure volume in China for FY24[24] - The company expects performance to rebound in the second half of 2025 as government stimulus takes hold[24]